Literature DB >> 24119083

Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy.

Ka-Te Huang1, Yue-Han Huang, Peng Li, Bin He, Zhen-Kun Chen, Xia Yu, Jian-Ou Chen, Qi-Yu Zhang, Hong-Qi Shi, Yun-Feng Shan.   

Abstract

AIM: Tuberous sclerosis complex 2 (TSC2), a tumor suppressor, may play an essential role in the regulation of cell growth and cell survival under energy stress conditions. In addition, TSC2 may act in concert with Wnt and energy signals by additional phosphorylation of glycogen synthase kinase 3β (GSK3β) to regulate cell growth. The expression levels and function of TSC2 and GSK3β in hepatocellular carcinoma (HCC) remain unclear.
METHODS: The protein levels of TSC2 and GSK3β were measured by immunohistochemistry in normal liver (n = 20), HCC (n = 80) and pericancerous tissues (n = 80). The correlations between TSC2, and GSK3β levels, clinicopathological features and patient survival were also analyzed.
RESULTS: The protein levels of TSC2 and GSK3β in HCC tissues were significantly lower than that in normal liver tissues and pericancerous tissues (P < 0.05). Decreased TSC2 and GSK3β expression was found to be significantly correlated with advanced clinicopathological characteristics and poor prognosis. The results also showed that TSC2 protein levels were associated with GSK3β expression in HCC specimens.
CONCLUSION: This is the first demonstration that the decreases in TSC2 and GSK3β levels may be associated with vascular invasion, histological grade and tumor-node-metastasis classification.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  expression; glycogen synthase kinase 3β; hepatectomy; hepatocellular carcinoma; prognosis; tuberous sclerosis complex 2

Year:  2013        PMID: 24119083     DOI: 10.1111/hepr.12256

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  11 in total

1.  6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.

Authors:  Esther Chon; Brandi Flanagan; Lucas Campos de Sá Rodrigues; Caroline Piskun; Timothy J Stein
Journal:  Vet J       Date:  2014-07-31       Impact factor: 2.688

2.  Recurrent genetic alterations in hepatitis C-associated hepatocellular carcinoma detected by genomic microarray: a genetic, clinical and pathological correlation study.

Authors:  Yajuan J Liu; Yang Zhou; Matthew M Yeh
Journal:  Mol Cytogenet       Date:  2014-11-25       Impact factor: 2.009

3.  GSK-3β suppresses HCC cell dissociation in vitro by upregulating epithelial junction proteins and inhibiting Wnt/β-catenin signaling pathway.

Authors:  Jing-Hua Zhang; Li-Yan Jiao; Tie-Jun Li; York Yuanyuan Zhu; Jian-Wei Zhou; Jian Tian
Journal:  J Cancer       Date:  2017-06-03       Impact factor: 4.207

4.  TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.

Authors:  Daniel W H Ho; Lo K Chan; Yung T Chiu; Iris M J Xu; Ronnie T P Poon; Tan T Cheung; Chung N Tang; Victor W L Tang; Irene L O Lo; Polly W Y Lam; Derek T W Yau; Miao X Li; Chun M Wong; Irene O L Ng
Journal:  Gut       Date:  2016-12-14       Impact factor: 23.059

Review 5.  Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.

Authors:  James A McCubrey; Timothy L Fitzgerald; Li V Yang; Kvin Lertpiriyapong; Linda S Steelman; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Luca M Neri; Lucio Cocco; Alberto M Martelli; Piotr Laidler; Joanna Dulińska-Litewka; Dariusz Rakus; Agnieszka Gizak; Ferdinando Nicoletti; Luca Falzone; Saverio Candido; Massimo Libra
Journal:  Oncotarget       Date:  2017-02-21

6.  Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma.

Authors:  Na Zhang; Xiaojia Liu; Lu Liu; Zhesong Deng; Qingxuan Zeng; Weiqiang Pang; Yang Liu; Danqing Song; Hongbin Deng
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

7.  TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of Hepatocellular carcinoma.

Authors:  Jinming Wei; Linsen Ye; Laien Song; Hui Tang; Tong Zhang; Binsheng Fu; Yingcai Zhang; Qing Yang; Yang Yang; Shuhong Yi
Journal:  J Gastrointest Oncol       Date:  2021-06

Review 8.  GSK-3 as potential target for therapeutic intervention in cancer.

Authors:  James A McCubrey; Linda S Steelman; Fred E Bertrand; Nicole M Davis; Melissa Sokolosky; Steve L Abrams; Giuseppe Montalto; Antonino B D'Assoro; Massimo Libra; Ferdinando Nicoletti; Roberta Maestro; Jorg Basecke; Dariusz Rakus; Agnieszka Gizak; Zoya N Demidenko; Lucio Cocco; Alberto M Martelli; Melchiorre Cervello
Journal:  Oncotarget       Date:  2014-05-30

9.  Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Authors:  Jeong Su Park; Soo Han Bae
Journal:  Clin Mol Hepatol       Date:  2020-09-17

10.  TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy.

Authors:  Kangjian Song; Fu He; Yang Xin; Ge Guan; Junyu Huo; Qingwei Zhu; Ning Fan; Yuan Guo; Yunjin Zang; Liqun Wu
Journal:  Pharmgenomics Pers Med       Date:  2021-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.